Nephrogenic fibrosing dermopathy (NFD) causes thickening and hardening of the skin, often in the extremities, and occurs in patients with underlying renal disease. The skin lesions can progress rapidly, sometimes leading to joint immobility and the inability to walk (1). In May 2006, nephrologists at hospital A in St. Louis, Missouri, reported to CDC and the Missouri Department of Health and Senior Services (MoDHSS) a cluster of NFD among patients treated in their dialysis units. CDC and MoDHSS conducted an investigation to determine the number of affected patients and identify risk factors for NFD. Thirty-three patients with NFD were identified in St. Louis, 28 of whom had been treated at hospital A. A matched case-control study was conducted at the hospital. This report summarizes the preliminary results of that study, which indicated that exposure to gadoliniumcontaining contrast agents during magnetic resonance imaging (MRI) studies was independently associated with NFD. Clinicians should be aware of the potential for NFD, and when possible, should avoid use of gadolinium-containing contrast agents in patients with advanced renal disease.
Nephrogenic Fibrosing Dermopathy Associated with Exposure to Gadolinium-Containing Contrast Agents -St. Louis, Missouri, 2002-2006
Nephrogenic fibrosing dermopathy (NFD) causes thickening and hardening of the skin, often in the extremities, and occurs in patients with underlying renal disease. The skin lesions can progress rapidly, sometimes leading to joint immobility and the inability to walk (1) . In May 2006, nephrologists at hospital A in St. Louis, Missouri, reported to CDC and the Missouri Department of Health and Senior Services (MoDHSS) a cluster of NFD among patients treated in their dialysis units. CDC and MoDHSS conducted an investigation to determine the number of affected patients and identify risk factors for NFD. Thirty-three patients with NFD were identified in St. Louis, 28 of whom had been treated at hospital A. A matched case-control study was conducted at the hospital. This report summarizes the preliminary results of that study, which indicated that exposure to gadoliniumcontaining contrast agents during magnetic resonance imaging (MRI) studies was independently associated with NFD. Clinicians should be aware of the potential for NFD, and when possible, should avoid use of gadolinium-containing contrast agents in patients with advanced renal disease.
A confirmed case was defined as clinical findings (i.e., skin thickening or hardening) and skin biopsy findings consistent with NFD in a person with renal disease in St. Louis during January 2000-August 2006. Suspected cases met either the clinical or the biopsy criteria but not both. Hospital A staff members manually searched a logbook of dermatology biopsies to identify diagnoses consistent with NFD from January 2000 onward. Study investigators searched the hospital pathology database for diagnoses of NFD and potentially related diagnoses from the same period. Investigators searched for additional cases that would not have been identified at hospital A by contacting eight pathology referral centers in St. Louis and requesting information on all patients who had NFD diagnosed since January 2000.
Demographics, comorbid conditions, and medication data for case-patients and controls were collected from hospital A inpatient and outpatient medical records, which included information from hospital A admissions (including emergency department visits), outpatient dialysis and other clinic visits, and laboratory and radiology studies performed in the hospital A system. The maximum erythropoietin (epoetin alfa) dose received during the preceding 6 months and the dose received at the time of disease detection (for case-patients) or match date (for controls) were classified as high or low relative to the median weekly dose received by all patients in the study. Continuous variables were compared using the Wilcoxon ranksum test, and categorical variables were compared using a chi-square test or Fisher's exact test. Matched univariate odds ratios (ORs) were calculated. After adjusting for clinically relevant variables determined to be associated within the univariate analysis, multivariable ORs were calculated using a conditional logistic regression model.
The case-control study included confirmed cases from hospital A. Three controls per case-patient were selected randomly from a group of patients who were treated in the same hospital A dialysis clinic or treatment center on the same day that a case was diagnosed. These matched controls were required to have received dialysis for at least 4 weeks or to have had renal insufficiency (serum creatinine >2.5 mg/dL) for at least 6 months preceding their match date. Only case-patients and controls with medical record information available for at least 3 of the 6 months preceding the match date were included.
Twenty-eight cases were identified at hospital A during December 2002-August 2006, including 25 confirmed and three suspected cases (Figure) . Five additional patients from St. Louis with NFD outside of hospital A were identified during the study period; however, minimal information was available for these patients, and they were excluded. Among the 19 confirmed case-patients at hospital A who met criteria for inclusion in the case-control study, the median age was 50 years (range: 21-67), and 10 (53%) were male. The median number of months on dialysis was 30 (range: 0.1-192 months). The primary type of dialysis received in the 6 months preceding disease detection was hemodialysis for 11 (58%) of the 19 case-patients and peritoneal dialysis for six (32%) casepatients. Two of the 19 case-patients had acute renal failure and received dialysis only for a brief time (4 days for one patient, 45 days for the other) during the 6 months preceding disease diagnosis. The clinical sites at which NFD was first detected were hospital A during inpatient hospitalization for 13 (68%) case-patients, an outpatient peritoneal dialysis clinic affilitated with hospital A for four (21%) case-patients, and an outpatient hemodialysis unit affiliated with hospital A for two (11%) case-patients. .40 * Case-patients: n = 19; controls: n = 57 (N = 76). Case-control study included confirmed cases from hospital A. Controls were matched to each case by date and clinical site of case-patient at time of disease detection. Controls were required to have received dialysis for at least 4 weeks or demonstrate renal insufficiency (serum creatinine >2.5 mg/dL) for at least 6 months preceding their match date. † Continuous variables were compared using the Wilcoxon rank-sum test, and categorical variables were compared using a chi-square test or Fisher's exact test. Significance set at p<0.05. § N = 75. ¶ N = 67.
Five case-patients had no identified gadolinium exposure within 1 year preceding NFD diagnosis. However, of these, four had gadolinium exposure from 16 to 68 months preceding diagnosis; the fifth patient had no evidence of gadolinium exposure. Among case-patients (n = 14) and controls (n = 14) with gadolinium-containing contrast exposure in the preceding year, case-patients were more likely to have received peritoneal dialysis as their primary type of dialysis in the preceding 6 months (36% versus 0%) and had a longer median time on dialysis (27 months versus 10 months). Thirteen patients (nine case-patients, four controls) had multiple gadolinium-containing contrast exposures during the preceding year. The NFD attack rate estimated for persons undergoing outpatient chronic dialysis in the hospital A system for the 4 years in which cases were identified was 4.6 cases per 100 peritoneal dialysis patients and 0.61 cases per 100 hemodialysis patients.
Intravenously administered contrast agents are used routinely for MRI studies; the contrast agents contain gadolinium (a paramagnetic heavy metal), which is bound to a chelating agent. The mechanism for possible gadoliniumassociated NFD is unknown; however, one hypothesis is that the gadolinium ions might dissociate from the chelate and result in a fibrotic reaction (5) . Five gadolinium-based contrast agents are available in the United States; the first was approved for use in 1988 (7) . Adverse events associated with these agents typically are minor (e.g., nausea); severe effects such as allergic reactions or tissue necrosis as a result of extravasation are rare. In addition, gadolinium-containing contrast agents are believed to be less nephrotoxic than iodinated contrast agents used for computed tomography (CT) imaging (8) . Excretion of gadolinium-containing contrast agents primarily occurs renally; the amount of contrast eliminated from the body after dialysis has not been wellevaluated. Two studies suggest that 65%-78% of gadolinium-containing contrast might be cleared after one hemodialysis session and 98% after three sessions (9, 10) . Peritoneal dialysis might achieve less effective gadoliniumcontrast clearance than hemodialysis. In one study, 69% of total gadolinium-containing contrast was excreted after 22 days in patients undergoing continuous ambulatory peritoneal dialysis (9) . Delayed clearance might prolong the duration of gadolinium-containing contrast exposure among patients undergoing peritoneal dialysis. However, patients undergoing peritoneal dialysis have not been previously reported to be at higher risk for NFD than patients undergoing hemodialysis. The chronic peritoneal dialysis outpatients in this investigation had higher estimated NFD attack rates than chronic hemodialysis outpatients. No controls who had gadoliniumcontaining contrast exposure underwent primarily peritoneal dialysis.
The number of cases identified at hospital A decreased during the second and third quarters of 2006 ( Figure) , and the reason for this decrease is unclear. Because NFD was not recognized at hospital A until late 2002, initially identified cases likely represented both incident (new) and prevalent (existing) cases; the decline might represent the subsequently smaller number of remaining prevalent cases that had not been identified. Although hospital A instituted changes such as limiting the use of gadolinium-containing contrast agents in patients with renal failure, these changes were initiated shortly before the investigation began and are unlikely to account completely for the decline.
The findings in this report are subject to at least two limitations. First, NFD is a rare condition. Even though the data in this report represent the largest cluster of NFD cases identified to date, the small sample size of the case-control study might have limited the power to demonstrate statistically significant associations for variables other than exposure to gadolinium-containing contrast agents. Second, the date of disease diagnosis was used instead of date of disease onset; the actual date of disease onset is unknown. To identify exposures that preceded the actual date of disease onset, exposures as early as 1 year before the date of diagnosis were included. This might have resulted in the inclusion of gadolinium exposures that were not related to the development of NFD. When possible, use of gadolinium-containing contrast agents should be avoided in patients with advanced renal failure, particularly in patients who are undergoing peritoneal dialysis. Depending on the indication for imaging, other radiologic modalities (e.g., ultrasound and CT) might be acceptable substitutes in certain situations. If gadolinium-containing contrast is medically necessary, prompt hemodialysis after contrast administration to facilitate clearance of the contrast might be reasonable for patients who have established hemodialysis access; however, the effectiveness of this strategy in reducing the risk for NFD development or progression is unknown. Among patients with no other indication for chronic or acute hemodialysis, the risks of establishing hemodialysis access should be weighed against theoretical benefits of hemodialysis after gadolinium-containing contrast administration. CDC and FDA are collaborating to assess potential differences among gadolinium-containing contrast agents, including the associated risk for NFD and possible related factors. Additional studies are needed to assess the ability of peritoneal dialysis and hemodialysis to clear gadoliniumcontaining contrast agents and to clarify the mechanism by which use of gadolinium or chelating agents might result in NFD. Clinicians who treat patients with renal disease should be aware of the risk for NFD and consider the diagnosis in patients with characteristic skin lesions. Suspected adverse drug events should be reported to FDA via the MedWatch program by phone (1-800-FDA-1088), by fax (1-800-FDA-0178), or online (http://www.fda.gov/medwatch/index.html). containing contrast agents for magnetic resonance imaging (MRI):
Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Chagas disease has an acute stage, typically asymptomatic or with mild symptoms (e.g., fever, malaise, swelling at the site of innoculation and lymphadenopathy) during the first 6-8 weeks after infection. If not treated, infection is lifelong with low-level, intermittent parasitemia. The majority of infected persons remain asymptomatic in the chronic indeterminate phase (i.e., a prolonged period of clinically silent infection that follows acute primary infection). However, an estimated 30% will have onset of chronic symptomatic disease, usually decades after the initial infection, with cardiac manifestations (e.g., cardiomyopathy, arrhythmias, and sudden death) or gastrointestinal involvement (e.g., megaesophagus or megacolon).
In the United States, vector-borne transmission of Chagas disease is rare (2) . However, one study revealed an increasing Chagas seroprevalence among blood donors in Los Angeles County, California, from 1996 (one in 9,850 donors) to 1998 (one in 5,400 donors) (7) . In 1991, a questionnaire was introduced to screen blood donors; those reporting a history of Chagas disease are deferred, but most persons with Chagas disease likely are unaware of their infections. Seven cases of transfusion-associated transmission have been documented in the United States and Canada during the past 20 years; all occurred in immunosuppressed recipients (3) (4) (5) (6) . Because acute infections often are asymptomatic and the level of awareness of Chagas disease among clinicians is low, cases of transfusionassociated transmission can go undetected.
In 2005, a new commercial test for blood-donation screening for Chagas disease was developed. The test, manufactured by Ortho-Clinical Diagnostics (Raritan, New Jersey), is an enzyme-linked immunosorbent assay (ELISA) that uses epimastigote lysate antigens for detection of antibodies to T. cruzi in serum and plasma (8) . In clinical trials evaluating the test, including the American Red Cross study, blood donor specimens with initially reactive results were retested twice and considered repeat reactive if one or both of the repeat tests were reactive. Repeat reactive specimens from the clinical trials underwent further testing using a radioimmunoprecipitation assay (RIPA); those with positive RIPA results were considered confirmed positive. However, FDA has not licensed a supplemental test as a confirmatory assay in blood donation screening for T. cruzi antibodies.
After a clinical trial in 2005 with approximately 40,000 blood donors resulted in only one repeat reactive specimen (which tested negative with RIPA) (8) , the American Red Cross conducted a larger study of the new screening assay in areas where Chagas was expected to be more prevalent. The study was conducted in three collection facilities of the American Red Cross, including the Southern California Region (Los Angeles, California), the Northern California Region (Oakland, California), and the Arizona Region (Tucson, Arizona). Blood donations collected during August 28, 2006-January 28, 2007, were tested with the screening assay for those blood donors willing to participate in the study. All donors were asked to participate; 78.5% agreed, and their specimens were tested.
A total of 148,969 blood-donation specimens were tested; 63 specimens from 61 donors were repeat reactive for T. cruzi antibodies (approximately one in 2,365 donations). Among the 61 donors with repeat reactive speciments, 40 (66%) were male; the age range was 17-84 years, with a mean age of 47 years and a median of 50 years. Of the 63 repeat reactive specimens, 50 (79%; one in 1,993 donations) were collected from the Los Angeles center, nine (14%; one in 3,258 donations) were collected from the Oakland center, and four (6%; one in 5,995 donations) were collected from the Tucson center. Fiftyfive (90%) of the 61 donors were allogeneic donors; the remaining six included five autologous donors (two with two reactive donations each) and one directed donor. Of the 55 allogeneic donors, 18 (33%) were first-time donors, and 37 (67%) had donated blood previously. All of the 63 repeat reactive donations were tested with RIPA, of which 32 (51%) were positive and 31 (49%) were negative.
On December 13, 2006, based in part on preliminary results from the American Red Cross study, FDA licensed the Ortho T. cruzi ELISA Test System to screen blood donors in the United States. The new assay also is labeled for testing plasma and serum samples from living cell and tissue donors and from heart-beating organ donors, but is not labeled for general clinical diagnostic use.
* Available at http://www.aabb.org/content/members_area/association_bulletins/ ab06-08.htm.
the American Red Cross and Blood Systems, Inc., bloodcollection organizations that are responsible for approximately 65% of the U.S. blood supply, began screening all donations for T. cruzi on January 29, 2007, and providing testing services for smaller blood-collection centers and hospitals that requested testing. FDA is expected to recommend implementation of the test by all blood-collection establishments.
The AABB (formerly known as the American Association of Blood Banks) has issued recommendations to its member facilities regarding how to use the new test.* AABB recommends that all components from blood donations that are repeat reactive by the ELISA test should be quarantined and removed from distribution, and the donor should be deferred from making donations indefinitely. Recipient tracing should be conducted to identify and test recipients of blood components collected previously from donors who are confirmed positive (i.e., repeat reactive by ELISA and positive by RIPA). AABB also suggests testing at-risk family members of donors who are confirmed positive or family members with a similar history of exposure to vectors in an endemic area (e.g., the children of seropositive women). Deferred donors, at-risk family members, and potentially infected recipients should be referred to health-care providers for evaluation and management.
Screening blood donations for T. cruzi antibodies can identify persons with previously undiagnosed Chagas disease and further enhance the safety of the U.S. blood supply. However, as with any screening test, limitations exist. Although available data regarding the performance of the new assay have suggested high sensitivity and specificity (8, 9) , some falsenegative results have occurred with this assay (8) and with other assays used to screen for T. cruzi antibodies (10) . In addition, when a screening assay is used in a population with low disease prevalence, a greater proportion of false-positive results can be expected. Donors with reactive screening assay results require further clinical diagnostic testing to verify T. cruzi infection and to guide clinical management.
For clinical purposes, no single laboratory test is adequately sensitive and specific to diagnose Chagas disease. Diagnosis generally is made by using at least two different serologic tests (e.g., diagnostic ELISA tests, immunofluorescence assay, or indirect hemagglutination) (1) and by considering clinical findings and exposure risk. Clinical diagnostic testing for Chagas disease is available through commercial laboratories and the Division of Parasitic Diseases (DPD) at CDC. After diagnosis, health-care providers should conduct a thorough clinical evaluation to determine the stage of disease, develop an appropriate treatment plan, and provide information regarding prognosis. CDC is preparing guidance for the clinical evaluation, staging, management, and treatment of patients with Chagas disease.
Cases of Chagas disease likely will be increasingly identified as a result of screening blood donors for infection with T. cruzi. In addition, requests for diagnostic testing might become more frequent as awareness of Chagas disease increases among clinicians and the general public. Most identified cases likely will represent chronic infections that were acquired years earlier.
Chagas treatment options are limited and are most effective during the acute stage of infection. However, increasing evidence suggests that treatment of persons with chronic infections can result in seroreversion and prevent progression of cardiac morbidity (1) . Treatment of women of childbearing age with Chagas disease can decrease the risk for congenital transmission. Antitrypanosomal medication in the United States is currently available only through CDC under an investigational new drug protocol.
Questions regarding laboratory diagnosis, evaluation, and management of Chagas disease can be posed to DPD by telephone, 770-488-7775. Additional information regarding Chagas disease is available at http://www.cdc.gov/ncidod/dpd/ parasites/chagasdisease/default.htm.
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Measles Among Adults Associated with Adoption of Children in China -California, Missouri, and Washington, July-August 2006
On August 15, 2006, the Missouri Department of Health and Senior Services (MoDHSS) was notified of a measles case in a Missouri resident who had recently traveled to China. The patient had traveled with a group of 11 families seeking to adopt children from three orphanages in Guangdong Province. Members of the group, which was sponsored by a Missouri-based adoption agency, traveled separately but stayed at the same hotel in Guangdong Province during July 13-27. This report describes the multistate investigation that followed, which identified two additional measles cases. None of the three patients recalled contact during travel with anyone who appeared ill. All three patients recovered fully, and no secondary cases were identified among family members, other travelers, patients, or medical staff who might have been exposed. Because of delays in diagnoses (the earliest case was identified 2 weeks after rash onset), no control measures (e.g., vaccination of contacts or administration of immunoglobulin) were indicated. Communicable diseases that are no longer endemic in the United States continue to occur among travelers, often resulting in delayed recognition and delayed notification of public health authorities. Because of the risk for spread in the community of imported communicable diseases such as measles (1), thorough investigation is needed to determine possible sources of infection and the extent of disease spread in the community. Case 1. On July 13, a woman from Missouri aged 36 years traveled with her husband to Guangdong Province. She returned to the United States on July 28 with her husband and their adopted child. On July 30, she had onset of fever. The next day, a rash appeared on her face and trunk. On August 2, she sought medical care and was tested for tickborne illnesses endemic in rural Missouri (e.g., Rocky Mountain spotted fever and ehrlichiosis). On August 9, a measles immunoglobulin M (IgM) antibody test was obtained, which was reported positive on August 14. The patient had received 2 documented doses of measles-containing vaccine (MCV) in her lifetime (1 dose at age 11 months and another at age 10 years). She and her husband had stayed at the same hotel as 10 other U.S. families while awaiting finalization of their adoptions. On August 15, the CDC Division of Global Migration and Quarantine (DGMQ) was asked to assist in contacting potentially exposed passengers on both a trans-Pacific flight and a domestic flight, on which the patient had flown during her return trip from China. On August 18, a list of trip participants was obtained from the adoption agency. MoDHSS contacted each family by telephone and identified two additional cases of rash illness (cases 2 and 3) in persons from the adoption group.
DGMQ collaborated with MoDHSS to obtain the passenger manifests (i.e., lists of passengers and their seating assignments) and available passenger-locator information (i.e., personal contact information for passengers) for potentially exposed passengers on the international and domestic U.S. flights on which the patient from Missouri had flown. Six passengers seated near the patient on the international flight were identified as potentially exposed; all six were contacted, and none reported symptoms consistent with measles during one incubation period (7-21 days) after the flight. The passenger manifest and passenger-locator information for all passengers on the domestic U.S. flight were obtained because no seating was assigned for the flight.
Contact information was available for 101 of 118 passengers. DGMQ provided that information to the state health departments in states where passengers resided. The number of passengers who were contacted by the state health departments is unknown. No measles cases associated with this flight were reported to CDC. Case 2. On August 2, a woman from California aged 39 years, who had been part of the same adoption trip, had onset of a maculopapular rash on her face, chest, and back. She had returned from China on July 28 and thus was not considered infectious* during her return travel to the United States. She had no fever, coryza, cough, or conjunctivitis. MoDHSS learned of this patient's symptoms while interviewing the patient from Missouri and notified the California Department of Health on August 16. A measles IgM antibody titer was obtained and was positive. The patient reported receiving at least 2 doses of MCV in her lifetime, for which no documentation was available.
Case 3. On July 29, a woman from Washington aged 38 years was evaluated in the emergency department of a military hospital for fever (102.9°F [39.4°C]) and a maculopapular rash on her chest and face. She described headache, facial swelling, cough, nasal congestion, nausea, and diarrhea that began July 27 while en route from China to Seattle. Her symptoms initially were attributed to amoxicillin she was taking for sinusitis diagnosed before her travel, and the drug was discontinued. On July 31, approximately 48 hours after discontinuing the antibiotic, she returned to the hospital with continued fever and rash that had progressed to her trunk and arms. She was hospitalized for 4 days to evaluate her symptoms and elevated levels of hepatic transaminases. Viral hepatitis studies were negative. The patient improved and was discharged home. On August 21, MoDHSS notified the Washington State Department of Health (WSDH) that the woman had traveled with the adoption group. Serum obtained on August 22 by the local health department was reactive for measles IgM antibody. The patient had received 1 documented MCV dose at age 1 year.
WSDH and CDC were unable to identify contacts of the patient from Washington on the international flight because a manifest from the carrier could not be obtained. For the interstate flight, the delay in receiving notification of the patient's illness meant that the airline was unable to provide the manifest for the indicated flight in a timely manner. Therefore, a manifest was not requested by WSDH. (1, 3, 4) . Imported measles cases among adoptees from China have been reported previously (4, 5) . This report documents imported measles cases during July-August 2006 among adopting parents from the United States who were exposed to measles while visiting China.
China is the leading country of origin for foreign-born children adopted in the United States (6). During 1998-2005, annual U.S. adoptions of children from China increased by 88%, from 4,206 to 7,906 (6) . A national measles outbreak in China increased reported measles cases there from 70,549 in 2004 to 124,219 in 2005 (7). In Guangdong Province, 11,146 measles cases were reported during January-June 2006, a 30% increase compared with the same period in 2005 (8) . This situation in China presented an increased risk for measles exposure to travelers and potential importation into the United States. China has set a measles-elimination goal for 2012, and the country is conducting activities to achieve this goal (e.g., conducting an international field review [November 2006] and convening the first National Technical Advisory meeting on measles elimination [December 2006] ).
According to the Advisory Committee on Immunization Practices (ACIP), persons born during 1957 or later without 1) adequate documentation of immunity by previous vaccination with 2 doses of MCV, 2) laboratory evidence of immunity, or 3) physician-diagnosed measles should be vaccinated with the measles, mumps, and rubella (MMR) vaccine before travel abroad (9) . The U.S. Department of State requires that internationally adopted children aged >10 years receive the following vaccines before entry into the United States: measles, mumps, and rubella; polio; tetanus and diphtheria toxoids; pertussis; Haemophilus influenzae type B; hepatitis B; varicella; and pneumococcal. For those aged <10 years, the adopting parents must sign an affidavit promising to provide these vaccinations within 30 days of entry to the United States. The education that most adoptive parents receive regarding their own medical preparations before travel can vary substantially. In this instance, the adoption agency provided the ACIP recommendations to the clients and repeatedly advised their clients about the importance of being properly vaccinated; however, no standard mechanisms were in place to ensure that these recommendations were followed before travel abroad. In the United States and internationally, several organizations (e.g., the American Academy of Pediatrics Section on Adoption and Foster Care and the Joint Council for International Children's Services) are working to improve immunization and education standards regarding international adoptions. Health-care providers should continue to promote appropriate pretravel vaccination for their patients.
Investigation of all three cases was substantially delayed because of delays in diagnosis and delays in notifying jurisdictions where exposed travelers resided. Because measles is rare in the United States (as a result of high immunization levels), it is often unrecognized by clinicians who might not consider measles in a differential diagnosis. Health-care providers should routinely gather information regarding the patient's travel history and maintain a high level of suspicion for measles in patients with rash, fever, and recent travel to areas of known measles endemicity. Although a single dose of measles vaccine administered in the second year of life induces immunity in 95% of vaccinees (10), cases can occur even among vaccinated persons. More common than vaccine failure is incomplete documentation or inaccurate recall of vaccination status. In the cases described in this report, the patient from Missouri had 2 MCV doses documented, the patient from Washington had 1 MCV dose documented, and the patient from California had no MCV doses documented.
DGMQ is authorized § to conduct investigations involving international flights arriving in the United States and can assist state health departments with investigations involving interstate flights. In the case of interstate flights, DGMQ may request passenger manifests and passenger-locator information to assist the state in which the plane lands. Once notified of an exposure, DGMQ contacts the airline to obtain the passenger manifest and passenger-locating information of contacts. A software application developed by DGMQ, eManifest, is used to securely import, sort, and assign passenger-locator information to jurisdictions. These data are transmitted securely to state and territorial health agencies via the Epidemic Information Exchange (Epi-X) forum. Staff from the 18 CDC quarantine stations follow up with public health agencies to ensure the information has been received. DGMQ continues to work with airlines to develop mechanisms for the timely provision of passenger-locator information to CDC and with federal and state partners to improve the process of distributing this information.
Notice to Readers

Supply of Vaccines Containing
Varicella-Zoster Virus CDC received notice from Merck & Co., Inc., that it has lower amounts of varicella-zoster virus (VZV) than expected from recently manufactured bulk vaccine. Bulk vaccine production is an intermediate step in the manufacture of VZVcontaining vaccines. Varicella bulk is stored frozen until it is needed in the final preparation phase of each vaccine. Production of VZV bulk has been suspended temporarily while the manufacturer identifies the cause of the low virus yield. Merck is the only U.S. supplier of VZV-containing vaccine, including varicella vaccine (Varivax ® ); combined measles, mumps, rubella, and varicella (MMR-V) vaccine (ProQuad ® ); and zoster vaccine (Zostavax ® ). This lower virus yield does not affect the quality of any of Merck's VZV-containing vaccines currently on the market, any lots of vaccine manufactured and ready for release to the market, or any VZV-containing vaccines presently being manufactured.
To conserve existing bulk vaccine with adequate VZV potency, Merck is prioritizing continued production of varicella and zoster vaccines over production of MMR-V vaccine. Merck is taking this approach because the production of varicella vaccine requires less VZV than the production of MMR-V vaccine. Although zoster vaccine requires a similar amount of VZV for production as MMR-V vaccine, projected supply needs for zoster vaccine are much lower than projected supply needs for MMR-V vaccine. Merck also will increase production of combined measles, mumps, and rubella (MMR) vaccine (M-M-R II ® ).
Current supply assessments in the United States indicate that this interruption in bulk vaccine supply will not affect the supply of either varicella vaccine or zoster vaccine. The U.S. varicella vaccine supply is expected to be adequate to fully implement the recommended immunization schedule for varicella vaccine for all age groups, including the routine 2-dose schedule for children at 12-15 months and at 4-6 years, catch-up vaccination with the second dose for children and adolescents who received only 1 dose, and vaccination with 2 doses for other children, adolescents, and adults without evidence of immunity (1-3). For zoster vaccine, the supply is expected to be adequate to vaccinate adults aged >60 years in accordance with current provisional vaccine policy recommendations (4) . The MMR-V vaccine supply is adequate to continue ordering this combination vaccine (5); however, the manufacturer expects supplies of MMR-V vaccine to be depleted toward the end of 2007, depending on market demand. When this occurs, supplies of separate MMR and varicella vaccines are expected to be adequate to fulfill the need for these two products in place of MMR-V vaccine. CDC will continue to work with Merck and vaccine-provider stakeholders to monitor the supply of VZV-containing vaccines. Updates on vaccine shortages and delays are available at http:// www.cdc.gov/nip/news/shortages/default.htm. -3  13  13  6  58  83  142  538  685  -0  2  -2  Louisiana  -0  6  2  --122  354  528  1,272  -0  3  2  -Oklahoma  2  2  11  15  12  -90  184  456  484  1  1  24  11  9  Texas§   N  0  0  N  N  235  577  932  2,986  3,504  -0  2  -1   Mountain  25  28  68  146  164  80  280  466  1,324  2,000  8  4  10  39  36  Arizona  5  3  10  31  26  8  117  231  422  670  5  2  6  21  13  Colorado  15  10  33  54  45  7  72  92  372  527  -1  4  8  12  Idaho§   1  3  12  12  24  -2  20  -24  -0  1  1  2  Montana§   -2  11  9  8  1  3  20  17  6  -0  0  --Nevada§   -1  8  6  4  64  30  135  231  343  -0  1  1  -New Mexico§   -1  6  6  8  -32  65  190  270  -0  2  2  6  Utah  4  7  25  25  47  -17  26  87  130  3  0  4  6  3  Wyoming§   -1  4  3  2  -2  5  5  3 0  -0  1  --Pacific  9  57  98  256  356  44  784  971  3,788  5,601  2  2  7  16  23  Alaska  -1  17  11  2  6  10  27  54  61  -0  2  4  2  California  -40  68  171  274  -640  833  3,016  4,665  -0  5  -2  Hawaii  -1  4  7  7  -15  30  53  138  -0  1  -2  Oregon§   8  8  12  49  66  17  28  46  154  209  2  1  4  12  16  Washington  1  7  42  18  7  21  77  142  511  528  -0 6  9  29  51  82  10  23  42  107  137  11  9  23  51  40  Delaware  -0  2  -1  -1  4  3  4  -0  2  1  1  District of Columbia  -0  5  5  1  -0  2  -1  -0  5  --Florida  3  3  13  23  26  6  8  16  44  55  6  3  10  21  18  Georgia  1  1  5  11  4  1  3  8  12  15  5  1  3  8  1  Maryland§   1  1  6  3  15  -2  7  12  30  -2  8  12  14  North Carolina  -0  20  1  28  -0  23  16  19  -0  5  3  3  South Carolina§   -0  3  2  4  -2  5  5  7  -0  2  2  -Virginia§   1  1  7  6  3  1  2  4  1 2  4  -1  5  3  3  West Virginia  -0  3  --2  0  7  3  2  -0  4 1 - -2  8  6  13  3  7  22  20  47  -2  9  6  6  Alabama§   -0  3  1  --2  1 3  9  1 6  -0  2  1  1  Kentucky  -0  5  2  2  -1  5  1  13  -0  5  3  1  Mississippi  -0  1  1  --0  4  -4  -0  2  --Tennessee§   -1  5  2  1 1  3  3  7  1 0  1 4  -1  7  2  4 W.S. Central  -6  20  2  24  1  18  102  31  60  -1  12  2  2  Arkansas§   -0  9  -2  -1  4  4  7  -0  1  -1  Louisiana  -0  4  2  1  -0  5  2  3  -0  2  --Oklahoma  -0  3  -1  -0  14  1  --0  6  --Texas§   -4  15  -20  1  14  83  24  50  -0  12  2  1   Mountain  5  5  12  29  53  1  3  8  12  28  3  2  9  14  7  Arizona  4  3  9  25  34  -0  2  -7  1  1  4 1  1 5  5 3  3 6  2 0 7  -1 1  2 4  4 3  5 3  -1  6  4  1 7  Alaska  -0  0  ---0  3  2  --0  0  --California  -13  48  30  193  -8  17  28  42  -1  6  4 17 7  19  260  44  51  -0  6  -5  -1  3  2  6  Connecticut  5  8  227  12  20  -0  3  ---0  2  1  2  Maine§   -2  34  20  10  -0  1  ---0  2  1  2  Massachusetts  -0  3  -13  -0  3  -4  -0  2  -2  New Hampshire  2  3  95  8  6  -0 3  3  16  12  12  -4  13  8  29  2  5  16  28  56  Alaska  1  0  1  1  --0  4  2  2  -0  1  -1  California  -2  14  9  12  -2  6  2  24  -3  10  19  33  Hawaii  N  0  0  N  N  -0  2  ---0  2  2  -Oregon§   2  0  2  2  --0  3  3  2  -0  4  4  1 5  Washington  -0  2  ---0  5  1  1  2  0  5  3  7 American Samoa -15  42  10  30  -0  1  ---1  25  5  1  Oklahoma  8  8  40  30  26  -0  17  1  -2  2  9  5  12  Texas§   -46  105  2  93  -2  23  1  1  3  29  161  45  77   Mountain  24  51  87  229  281  -8  35  10  25  10  26  87  73  111  Arizona  9  18  45  93  108  -2  13  5  11  6  11  35  41  62  Colorado  6  12  30  54  62  -1  8  1  6  2  3  15  9 -0  2  4  1  California  -89  158  264  416  -0  1  1  N  -28  76  69  176  Hawaii  -5  16  21  31  -0  2  1  1  -0  3  2  10  Oregon§   -8  16  27  50  -1  9  3  7  -1  6  8  41  Washington  9  10  58  30  14  3  2  13  3  3  1  2  13  8 13 28  21  49  176  243  2  2  8  20  22  16  42  114  211  235  Delaware  -0  0  ---0  0  ---0  3  2  5  District of Columbia  -0  3  1  7  -0  2  ---2  7  10  20  Florida  18  12  29  99  95  2  2  8  17  21  -15  23  68  100  Georgia  10  7  24  70  129  -0  1  -1  1  7  83  5  10  Maryland§   -0  0  ---0  0  --6  5  14  42  31  North Carolina  -0  0  ---0  0  --3  5  21  42  42  South Carolina§   -0  0  ---0  0  --2  1  5  1 4  1 1  Virginia§   N  0  0  N  N  -0  0  --4  3  17  28  16  West Virginia  -1  14  6  12  -0  1  3  --0  2 -- -2  11  22  38  2  0  2  3  5  5  14  29  83  69  Alabama§   N  0  0  N  N  -0  0  ---5  18  23  32  Kentucky  -0  3  6  7  -0  2  --1  1  9  11  6  Mississippi  -0  0  ---0  0  ---1  8  14  10  Tennessee§   -2  10  16  31  2  0  2  3  5  4  5  12 35 21 4  0  5  17  3  -0  1  -2  8  29  54  158  178  Arkansas§   -0  3  -3  -0  0  -2  1  1  7  1 2  1 1  Louisiana  -0  2  1  --0  1  ---5  27  17  14  Oklahoma  4  0  4  16  --0  0  ---1  4  12  8  Texas§   -0  0  ---0  0  --7  21  34  117  145   Mountain  -1  7  7  1 9  -0  5  1  7  -8  2 6  2 7  6 2  Arizona  -0  0  ---0  0  ---3  16  11  32  Colorado  -0  0  ---0  0  ---1 -0  4  ---0  2  --Louisiana  -1  9  14  4  -0  13  ---0  9  --Oklahoma  -0  0  ---0  6  ---0  4  --Texas¶   257  175  629  992  842  -0  38  ---0  16  --Mountain  93  61  137  424  539  -0  61  ---1  228  --Arizona  -0  0  ---0  9  ---0  15  --Colorado  46  24  76  179  357  -0  10  ---0 
QuickStats
from the national center for health statistics from the national center for health statistics from the national center for health statistics from the national center for health statistics from the national center for health- - 0 1 1 - 1 1 SARS-CoV §, § § § - - 0 - - - 8 N Smallpox § - - - - - - - - Streptococcal- - - 3 2 - N N Vancomycin-resistant Staphylococcus aureus § - - - - 3 1 N N Vibriosis (non-cholera Vibrio species infections) § - 8 - N N N N N Yellow fever - - - - - - - 1N 0 0 N N - 0 0 - - American Samoa U 0 46 U U U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico - 104 236 877 592 N 0 0 N N N 0 0 N N U.S. Virgin Islands U 5 16 U U U 0 0 U U U 0 0 U U MMWR February 23, 20071 - 1 American Samoa U 0 0 U U U 0 2 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico 1 2 15 4 5 - 6 13 36 47 - 0 2 - - U.S. Virgin Islands U 0 0 U U U 0 4 U U U 0 0 U U
New England
1 2 2 0 2 4 0 2 1 6 4 2 9 1 1 1 2 2 1 0 Connecticut 1 1 2 1 3 -0 2 -14 1 0 9 1 2 Maine§ - 0 2 - 1 - 0 2 - 3 - 0 2 - 1 Massachusetts - 0 4 - 26 - 0 3 - 9 - 0 4 - 6 New Hampshire - 0 16 1 7 - 0 1 - 3 - 0 1 - - Rhode Island § - 0 2 - 1 2 0 4 4 - - 0 6 - - Vermont § - 0 2 - 2 - 0 1 - - - 0 2 1 1
Mid. Atlantic
1 7 19 25 46 2 8 17 31 69 3 15 53 33 49 New Jersey -1 5 3 14 -2 6 3 25 -1 11 3 10 New York (Upstate) -1 11 6 5 1 1 8 6 3 1 6 30 8 7 New York City 1 2 11 10 16 -2 6 3 16 -2 18 2 13 Pennsylvania -1 5 6 11 1 3 7 19 25 2 5 19 20 19 E.N. Central 5 6 13 22 40 4 8 16 49 48 7 8 26 39 29 Illinois -1 4 2 9 -1 7 -8 -0 2 -7 Indiana -0 9 -3 1 0 9 1 --0 5 2 1 Michigan 2 2 8 12 14 3 3 8 22 24 1 3 10 14 7 Ohio 3 1 4 8 11 -2 10 23 14 6 4 19 23 8 Wisconsin -1 4 -3 -0 3 3 2 -0 3 -6
W.N. Central
1 2 8 8 2 0 -3 9 1 4 1 4 -1 1 5 8 4 Iowa- 0 1 1 - - 0 2 2 3 - 0 3 1 - Kansas - 0 5 - 13 - 0 2 - 3 - 0 2 - - Minnesota - 0 7 - - - 0 5 - - - 0 11 1 - Missouri - 1 3 4 4 - 1 6 9 8 - 0 2 5 4 Nebraska § - 0 2 1 1 - 0 3 2 - - 0 2 1 - North Dakota - 0 0 - - - 0 0 - - - 0 0 - - South Dakota 1 0 3 2 2 - 0 1 1 - - 0 1 - -
S. Atlantic
E.S. Central
3 - C o l o r a d o 1 1 3 3 7 - 0 4 2 7 - 0 2 2 2 Idaho § - 0 2 - 3 - 0 2 1 4 1 0 3 1 1 Montana § - 0 3 - 1 - 0 0 - - - 0 1 - - Nevada § - 0 1 1 3 - 0 4 5 6 - 0 2 2 3 New Mexico § - 0 2 - 3 - 0 2 3 3 - 0 1 2 - Utah - 0 2 - 2 1 0 5 1 1 1 1 6 4 1 Wyoming § - 0 1 - - - 0 1 - - - 0 0 - - PacificHawaii - 0 2 - 5 - 0 1 - - - 0 0 - - Oregon § 1 1 4 5 6 - 1 5 1 1 1 0 - 0 0 - - Washington - 0 4 1 3 - 1 8 2 1 - 0 0 - - American Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico - 1 9 4 6 - 1 9 3 2 - 0 4 - - U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U
New England
3 - - - 0 2 - - Rhode Island § - 0 9 3 - 1 - 0 1 - - - 0 1 - - Vermont § - 1 1 5 4 1 - 0 0 - 1 - 0 1 - -
Mid. Atlantic
11 143 566 333 370 -5 13 13 41 -2 11 12 30 New Jersey -25 186 52 139 -1 3 -12 -0 2 -3 New York (Upstate) 4 59 347 70 42 -1 7 3 3 -1 4 2 2 New York City -2 22 -4 -3 9 5 20 -1 4 3 12 Pennsylvania 7 43 234 211 185 -1 4 5 6 -0 4 7 13 E.N. Central -1 2 1 5 8 3 3 8 -2 7 8 1 8 6 2 1 2 1 5 1 6 Illinois- 0 0 - - - 1 5 2 7 - 0 3 - 7 Indiana - 0 3 - - - 0 3 - - 4 0 5 6 1 Michigan - 1 5 1 2 - 0 2 2 2 - 0 4 5 2 Ohio - 0 5 - 4 -1 - 0 1 1 - - 0 2 1 - Kansas - 0 2 1 - - 0 2 - - - 0 1 1 - Minnesota 5 2 167 12 8 - 0 12 4 2 - 0 3 - - Missouri - 0 2 - - - 0 1 1 1 - 0 3 5 3 Nebraska § - 0 2 - - - 0 1 2 - - 0 1 - 4 North Dakota - 0 0 - - - 0 1 - - - 0 1 1 - South Dakota - 0 1 - - - 0 0 - 1 - 0 1 1 - S.- - 0 1 - - - 0 2 - - E.S. Central - 0 3 2 - - 0 3 5 4 1 1 3 8 6 Alabama § - 0 3 - - - 0 2 - 1 1 0 2 2 1 Kentucky - 0 2 - - - 0 1 1 1 - 0 1 - 1 Mississippi - 0 1 - - - 0 1 1 1 - 0 2 2 1 Tennessee § - 0 2 2 - - 0 2 3 1 - 0 2 4 3 W.S. Central - 0 5 1 - - 1 7 2 5 3 1 4 8 5 Arkansas § - 0 0 - - - 0 2 - - - 0 1 - 2 Louisiana - 0 1 - - - 0 1 1 - - 0 2 1 - Oklahoma - 0 0 - - - 0 2 1 1 2 0 3 4 1 Texas § - 0 5 1 - - 1 6 - 4 1 0 3 3 2 Mountain - 0 3 2 1 - 1 6 - 9 2 1 4 9 1 7 Arizona - 0 2 - 1 - 0 3 - 2 - 0 2 2 7 C o l o r a d o - 0 1 - - - 0 2 - 3 1 0 2 1 7 Idaho § - 0 2 - - - 0 1 - - - 0 1 1 - Montana § - 0 1 1 - - 0 1 - - - 0 1 1 - Nevada § - 0 1 1 - - 0 1 - - - 0 0 - - New Mexico § - 0 1 - - - 0 1 - - - 0 1 1 - U t a h - 0 1 - - - 0 2 - 4 1 0 2 3 3 Wyoming § - 0 1 - - - 0 0 - - - 0 2 - - PacificU 0 0 U U U 0 0 U U U 0 0 - - C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 - - Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico N 0 0 N N - 0 1 - - - 0 1 1 - U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 - -C.- 0 0 - - - 0 1 1 - Idaho † 1 1 7 8 16 - 0 25 - - 1 0 3 1 - Montana † - 1 9 5 1 6 - 0 2 - - - 0 2 - - Nevada † - 0 6 - 5 - 0 0 - - - 0 0 - - New Mexico † - 2 8 3 6 - 0 2 - - - 0 2 - - Utah 17 13 39 41 76 - 0 1 1 - - 0 2 - - Wyoming † - 1 8 8 8 - 0 2 - - - 0 1 - - Pacific 8 2 8 2 2 8 2 9 1 2 9 - 4 1 2 1 8 1 0 - 0 1 - - Alaska - 1 8 8 16 - 0 6 14 3 N 0 0 N N California - 21 225 - 45 - 3 11 4 7 - 0 1 - - Hawaii - 1 6 2 24 N 0 0 N N N 0 0 N N Oregon † 1 1 8 6 3 0 - 0 4 - - - 0 1 - - Washington 7 5 46 13 14 - 0 0 - - N 0 0 N N American Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - - 0 0 - - N 0 0 N N Puerto Rico - 0 1 - - 1 1 6 7 12 N 0 0 N N U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U UnitedAmerican Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U U 0 0 U U Guam - 0 0 - - N 0 0 N N - 0 0 - - Puerto Rico 2 11 47 16 15 - 0 0 - - - 0 6 - 1 U.S. Virgin Islands U 0 0 U U U 0 0 U U U 0 0 U U - 0 1 1 - W e- 0 1 2 2 - 0 1 - 1 Montana § N 0 0 N N N 0 0 N N Nevada § - 0 3 3 - - 0 0 - - New Mexico § - 1 5 6 8 - 0 2 2 5 Utah 6 1 5 17 12 - 0 0 - - Wyoming § - 0 1 1 1 - 0 0 - - Pacific 1 2 9 1 4 1 8 2 0 1 4 - Alaska 1 0 2 5 N 2 0 1 4 - California N 0 0 N N N 0 0 N N Hawaii - 2 9 9 18 - 0 1 - - Oregon § N 0 0 N N N 0 0 N N Washington N 0 0 N N N 0 0 N N American Samoa U 0 0 U U U 0 0 U U C.N.M.I. U 0 0 U U U 0 0 U U Guam - 0 0 - - N 0 0 N N Puerto Rico - 0 0 - - N 0 0 N N U.S. Virgin Islands U 0 0 U U U 0 0 U U 0- 0 0 - - - 0 0 - - - 0 3 - 2 Kansas - 0 1 1 - - 0 0 - - 2 0 3 3 4 Minnesota - 0 50 - - - 0 10 - - - 0 3 6 9 Missouri - 1 3 10 8 - 0 1 - 1 - 3 9 8 16 Nebraska § - 0 1 - - - 0 0 - - - 0 2 - 1 North Dakota - 0 0 - - - 0 0 - - - 0 1 - - South Dakota - 0 3 - - - 0 1 1 - - 0 3 - -
S. Atlantic
E.S. Central
W.S. Central
